Simona Cristea
4.6K posts

Simona Cristea
@simocristea
director of applied AI @TempusAI; prev: faculty @DanaFarber, group leader @Harvard & phd @eth


Algorithms are part of nearly every aspect of life, from the physics of the natural world to planning shipping routes. Our Gemini-powered coding agent AlphaEvolve has been accelerating progress over the last year - from quantum and biotechnology to logistics and @Google’s AI infrastructure. ↓ goo.gle/4uzfe0C







There's a quadrillion-dollar question at the heart of AI: Why are humans so much more sample efficient compared to LLM? There are three possible answers: 1. Architecture and hyperparameters (aka transformer vs whatever ‘algo’ cortical columns are implementing) 2. Learning rule (backprop vs whatever brain is doing) 3. Reward function @AdamMarblestone believes the answer is the reward function. ML likes to use pretty simple loss functions, like cross-entropy. These are easy to work with. But they might be too simple for sample-efficient learning. Adam thinks that, in humans, the large number of highly specialised cells in the ‘lizard brain’ might actually be encoding information for sophisticated loss functions, used for ‘training’ in the more sophisticated areas like the cortex and amygdala. Like: the human genome is barely 3 gigabytes (compare that to the TBs of parameters that encode frontier LLM weights). So how can it include all the information necessary to build highly intelligent learners? Well, if the key to sample-efficient learning resides in the loss function, even very complicated loss functions can still be expressed in a couple hundred lines of Python code.


OTOH, when faced with simple, short papers which make a genuinely novel point, the LLM will sometimes tend to recommend rejection based on the paper not being complicated enough





Excited to share GeneBench, a genomics eval I've developed w/ @OpenAI that measures whether current models can execute realistic end-to-end scientific analyses where good scientific judgement is required. tl;dr they’re getting close, but aren’t quite there yet

Pancreatic cancer research at #AACR26: Dr. Brian Wolpin of @DanaFarber_Hale presents encouraging data on safety and efficacy from a small study combining the RAS inhibitor daraxonrasib with chemotherapy in patients with advanced #PancreaticCancer. @danafarber ➡️bit.ly/4cAoXMU








Remember when it was still an open question whether the undruggable could be drugged? Six years later, @RevMedicines has drugged the undruggable, and how they drugged it. What a time to be alive, what a time to practice! $RVMD


✈️ back from #AACR26 inspired and grateful. I haven’t missed an AACR Annual Meeting since 2012 and it remains my favorite. Grateful for the chance to speak and for the highly engaged audience at our team's talks and posters. Joy to reconnect with friends, colleagues and new faces









